Zurcher Kantonalbank (Zurich Cantonalbank) Iveric Bio, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$28 Billion
Q1 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$26.24 - $39.63 $34,951 - $52,787	1,332 Added 6.79%	20,954 $824,000
Q1 2023 May 08, 2023	BUY	$18.67 - $24.56 $26,847 - $35,317	1,438 Added 7.91%	19,622 $477,000
Q4 2022 Feb 01, 2023	BUY	$17.24 - $23.95 $91,647 - $127,318	5,316 Added 41.31%	18,184 $389,000
Q2 2022 Aug 09, 2022	SELL	$9.12 - $18.9 $1,249 - $2,589	-137 Reduced 1.05%	12,868 $124,000
Q1 2022 Apr 21, 2022	SELL	$12.15 - $16.83 $76,010 - $105,288	-6,256 Reduced 32.48%	13,005 $219,000

Q4 2021 Feb 01, 2022	SELL	$13.83 - $18.78 $11,354 - $15,418	-821 Reduced 4.09%	19,261 $322,000
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $1,795 - $4,445	254 Added 1.28%	20,082 $326,000
Q1 2021 May 03, 2021	BUY	$5.08 - $6.89 $2,697 - $3,658	531 Added 2.75%	19,828 $123,000
Q4 2020 Jan 28, 2021	BUY	$5.65 - $7.66 $109,028 - $147,815	19,297 New	19,297 $133,000

Others Institutions Holding ISEE

# of Institutions

Shares Held

250K

Call Options Held

40K

Put Options Held

View Full List

About IVERIC bio, Inc.

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

More about ISEE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account